Our laboratory previously reported that CD200 is overexpressed in patients with PDAC and that blockade of CD200 in a murine subcutaneous and genetically engineered mouse models reduced tumor burden, suggesting a pro-tumor role for CD200 in the context of pancreatic cancer [33]. The gene discussed is CD200; the disease is familial pancreatic carcinoma.